Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated mortality in the United States. Chemotherapy prolongs survival rates among patients with advanced disease, however, this is at the cost of clinically significant adverse effects. Matrine is an active component of traditional Chinese medicine and is a promising alternative drug for the treatment of NSCLC. In the present study, the therapeutic effects and the underlying molecular mechanisms of matrine on the A549 NSCLC cell line were investigated. A high concentration of matrine (1.0 mg/ml) significantly (P<0.05) inhibited cell proliferation, by 52.68±3.32%, under which cell shrinkage and disruption were observed. Flow cytometric analysis showed that the proportion of G1/G0 cells was significantly increased, whereas the proportions of S and G2/M cells were significantly decreased (P<0.05) following treatment with matrine for 48 h. These results indicated that cell arrest was induced by matrine. Upregulation of the expression of microRNA (miR)‑126, followed by downregulation of the expression of its target gene, vascular endothelial growth factor, were detected following treatment with a low concentration of matrine (0.2 mg/ml) using reverse transcription‑quantitative polymerase chain reaction analysis, immunohistochemistry and western blot analysis. In conclusion, matrine induced cell cycle arrest and apoptosis, and recovered the expression of miR‑126 in the A549 NSCLC cell line.
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Qi
Q
An
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Chao
C
Han
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Yubing
Y
Zhou
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Feng
F
Li
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Duolu
D
Li
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Xiaojian
X
Zhang
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Zujiang
Z
Yu
Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Zhenfeng
Z
Duan
Department of Clinical Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Quancheng
Q
Kan
D000072283:A549 Cells; D000470:Alkaloids / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D011807:Quinolizines / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics; D000093842:Matrines
D000470:Alkaloids; C527111:MIRN126 microRNA, human; D035683:MicroRNAs; D011807:Quinolizines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000093842:Matrines
Mol Pharmacol. 2003 Aug;64(2):382-94
12869643
Br J Cancer. 1998 Dec;78(12):1547-58
9862563
Zhong Yao Cai. 2003 Aug;26(8):566-9
14649201
Toxicology. 2007 Jan 18;229(3):245-52
17134813
Acta Pharmacol Sin. 2001 Feb;22(2):183-6
11741525
Planta Med. 2008 Feb;74(3):245-51
18283616
Leuk Res. 2001 Sep;25(9):793-800
11489473
Int J Oncol. 2001 Apr;18(4):767-73
11251172
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71
23054877
Lung Cancer. 2009 Nov;66(2):169-75
19223090
Clin Cancer Res. 2003 Jun;9(6):2316-26
12796401
PLoS One. 2010 Nov 08;5(11):e13881
21079729
Leuk Lymphoma. 2010 Jul;51(7):1337-46
20528251
J Exp Clin Cancer Res. 2009 Aug 12;28:112
19674474
J Clin Oncol. 2000 Jun;18(12):2354-62
10856094
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
22237781
Trends Mol Med. 2007 Aug;13(8):353-61
17644431
Hum Mol Genet. 2004 Oct 15;13(20):2443-9
15317748
Lancet Oncol. 2009 Nov;10(11):1033-4
19891056
Clin Cancer Res. 2009 May 1;15(9):3143-9
19383809
Oncogene. 2005 Jun 23;24(27):4462-71
15806155
CA Cancer J Clin. 1998 May-Jun;48(3):167-76; discussion 164-6
9594919
Hepatology. 2003 Feb;37(2):429-42
12540794
J Ethnopharmacol. 2004 Sep;94(1):117-22
15261971
World J Gastroenterol. 2005 Jan 21;11(3):426-8
15637760
Oncogene. 2006 Jun 26;25(27):3866-84
16799628
Am J Chin Med. 2003;31(3):337-54
12943166
Eur J Pharmacol. 2007 Jun 1;563(1-3):69-76
17343841
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2001 Aug;23 (4):333-6
12940071